Ainos Announces Successful Manufacturing Of VELDONA GMP Clinical Batch By Swiss Pharmaceutical
Portfolio Pulse from Benzinga Newsdesk
Ainos, Inc. has announced the successful manufacturing of a GMP Clinical Batch of VELDONA by Swiss Pharmaceutical Co., Ltd. Ainos plans to submit IND applications to the U.S. FDA for multiple candidates, including treatments for HIV Oral Warts, Sjogren's Syndrome, the Common Cold, and COVID-19, in the first half of 2024. The company is preparing for Phase II and III studies and has highlighted the potential of VELDONA as an immune response booster and antiviral agent.
November 28, 2023 | 1:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ainos, Inc. has completed a key manufacturing milestone for VELDONA and is progressing towards FDA IND submissions for several treatments, potentially boosting the company's profile and future revenue streams.
The successful manufacturing of the GMP Clinical Batch of VELDONA and the upcoming IND submissions to the FDA are significant positive developments for Ainos. These steps indicate progress in the company's pipeline and could lead to increased investor confidence and potential revenue growth from these treatments if approved. The focus on multiple disease areas, including COVID-19, could attract significant attention given the ongoing global health concerns.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100